{"id":"durvalumab-regimen-2","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Fatigue"},{"rate":"3-5","effect":"Pneumonitis"},{"rate":"15-25","effect":"Diarrhea"},{"rate":"10-20","effect":"Nausea"},{"rate":"10-15","effect":"Decreased appetite"},{"rate":"2-5","effect":"Immune-mediated hepatitis"},{"rate":"1-3","effect":"Immune-mediated colitis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Durvalumab binds to programmed death ligand 1 (PD-L1) expressed on tumor cells and immune cells, preventing engagement with PD-1 and PD-L2 receptors on T cells. This blockade removes the inhibitory signal that tumors use to evade immune surveillance, allowing T cells to recognize and attack cancer cells. Regimen 2 typically refers to a specific dosing or combination schedule in clinical trials.","oneSentence":"Durvalumab is a PD-L1 inhibitor that blocks the interaction between PD-L1 on tumor cells and PD-1/PD-L2 on immune cells, thereby restoring anti-tumor immune responses.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:46:15.515Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Unresectable stage III non-small cell lung cancer (NSCLC) after concurrent chemoradiotherapy"},{"name":"Metastatic or unresectable locally advanced urothelial carcinoma"},{"name":"Biliary tract cancer"}]},"trialDetails":[{"nctId":"NCT07055581","phase":"PHASE2","title":"Durvalumab as Consolidation for Patients LS-SCLC","status":"RECRUITING","sponsor":"Qian Chu","startDate":"2026-02-24","conditions":"Small Cell Lung Cancer Limited Stage","enrollment":100},{"nctId":"NCT07489976","phase":"PHASE2","title":"IIT2025-03-YANG-LIFT-HCC","status":"RECRUITING","sponsor":"Ju Dong Yang","startDate":"2026-04-01","conditions":"Hepato Cellular Carcinoma","enrollment":41},{"nctId":"NCT04092283","phase":"PHASE3","title":"Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-04-29","conditions":"Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8","enrollment":660},{"nctId":"NCT06694454","phase":"PHASE1, PHASE2","title":"Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-01","conditions":"Non-small Cell Lung Cancer (NSCLC), Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Carcinoma","enrollment":60},{"nctId":"NCT05771480","phase":"PHASE3","title":"Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-08-16","conditions":"Biliary Tract Cancer","enrollment":142},{"nctId":"NCT07174947","phase":"PHASE2","title":"SSRI Antidepressant Fluoxetine Improving Immunotherapy Efficacy in Advanced Hepatobiliary Malignancy Patients With Depression and Anxiety","status":"RECRUITING","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2025-10-01","conditions":"Hepatobiliary Malignancy, Fluoxetine, Anxiety Disorders","enrollment":240},{"nctId":"NCT03298451","phase":"PHASE3","title":"Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2017-10-11","conditions":"Hepatocellular Carcinoma","enrollment":1324},{"nctId":"NCT07175441","phase":"PHASE2","title":"Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Riboscience, LLC.","startDate":"2026-04","conditions":"Advanced Unresectable Hepatocellular Carcinoma","enrollment":220},{"nctId":"NCT05061550","phase":"PHASE2","title":"Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2022-04-14","conditions":"Non-small Cell Lung Cancer","enrollment":630},{"nctId":"NCT05733689","phase":"PHASE1","title":"Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)","status":"RECRUITING","sponsor":"University of California, Irvine","startDate":"2025-06-27","conditions":"Gastroesophageal Adenocarcinoma","enrollment":20},{"nctId":"NCT07459634","phase":"PHASE2","title":"A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC","status":"NOT_YET_RECRUITING","sponsor":"Jazz Pharmaceuticals","startDate":"2026-04-25","conditions":"Extensive-stage Small-cell Lung Cancer","enrollment":50},{"nctId":"NCT06859684","phase":"PHASE2","title":"Hepatic Arterial Infusion Chemotherapy (HAIC) Combined With Durvalumab and Lenvatinib in Patients With Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma: a Phase 2 Study(HAIC-quad Trial)","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2025-03-01","conditions":"Intrahepatic Cholangiocarcinoma (Icc), HAIC, Durvalumab","enrollment":25},{"nctId":"NCT05361395","phase":"PHASE1","title":"First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","startDate":"2022-08-24","conditions":"Extensive Stage Small Cell Lung Cancer","enrollment":184},{"nctId":"NCT06608940","phase":"PHASE1, PHASE2","title":"BC3402 w/ Tremelimumab + Durvalumab (STRIDE) in Hepatocellular Carcinoma","status":"WITHDRAWN","sponsor":"Case Comprehensive Cancer Center","startDate":"2025-11","conditions":"Hepato Cellular Carcinoma (HCC)","enrollment":""},{"nctId":"NCT04585477","phase":"PHASE2","title":"Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)","status":"RECRUITING","sponsor":"Stanford University","startDate":"2021-04-08","conditions":"Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage I, Non-small Cell Lung Cancer Stage II","enrollment":80},{"nctId":"NCT06904170","phase":"PHASE2, PHASE3","title":"Durvalumab and Tremelimumab With or Without Hepatic Arterial Infusion of Chemotherapy in Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2025-11-14","conditions":"Hepatocellular Carcinoma","enrollment":196},{"nctId":"NCT06333678","phase":"PHASE2","title":"A Study Comparing Sotorasib With Durvalumab in People With Non-Small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2024-03-20","conditions":"Non-Small Cell Lung Cancer","enrollment":10},{"nctId":"NCT04550260","phase":"PHASE3","title":"Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-10-19","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":640},{"nctId":"NCT07364305","phase":"PHASE2","title":"HAIC Combined With Immune Therapy for Advanced, Non-Resectable ICC","status":"RECRUITING","sponsor":"Eastern Hepatobiliary Surgery Hospital","startDate":"2025-01-01","conditions":"ICC, Advanced Cancer","enrollment":50},{"nctId":"NCT04748419","phase":"PHASE1, PHASE2","title":"Safety & Efficacy of Consolidative Hypofractionated Radiation Therapy for Boosting Residual Lung Cancer With Durvalumab","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Nebraska","startDate":"2021-07-15","conditions":"Lung Cancer, Carcinoma, Non-Small Cell Lung","enrollment":6},{"nctId":"NCT06124118","phase":"PHASE1","title":"Tumor Treating Fields for Locally Advanced NSCLC","status":"RECRUITING","sponsor":"University of Utah","startDate":"2024-04-04","conditions":"Non Small Cell Lung Cancer","enrollment":30},{"nctId":"NCT06680050","phase":"PHASE2","title":"Phase II Study of Radiotherapy Followed by Durvalumab and Ceralasertib in Stage III NSCLC Patients With Thoracic Relapses +/- Oligometastases After PACIFIC Regimen","status":"RECRUITING","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2025-08-07","conditions":"Non Small Cell Lung Cancer NSCLC","enrollment":21},{"nctId":"NCT04765709","phase":"PHASE2","title":"Durvalumab and Chemotherapy Induction Followed by Durvalumab and Radiotherapy in Large Volume Stage III NSCLC","status":"TERMINATED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2021-09-24","conditions":"Non-small Cell Lung Cancer Stage III","enrollment":10},{"nctId":"NCT03381183","phase":"PHASE1","title":"IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2019-08-21","conditions":"Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Metastatic Squamous Cell Carcinoma","enrollment":19},{"nctId":"NCT05568212","phase":"PHASE2","title":"Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and Durvalumab","status":"RECRUITING","sponsor":"Fondazione Ricerca Traslazionale","startDate":"2022-05-02","conditions":"Non-small-cell Lung Cancer Patients","enrollment":176},{"nctId":"NCT03983954","phase":"PHASE1","title":"Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.","status":"ACTIVE_NOT_RECRUITING","sponsor":"NeoTX Therapeutics Ltd.","startDate":"2019-10-10","conditions":"ER+ Breast Cancer, Ovarian Cancer, Cervical Squamous Cell Carcinoma","enrollment":120},{"nctId":"NCT03519971","phase":"PHASE3","title":"Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2018-03-29","conditions":"Non-Small Cell Lung Cancer","enrollment":328},{"nctId":"NCT06008093","phase":"PHASE3","title":"A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-04-04","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":280},{"nctId":"NCT04644289","phase":"PHASE2","title":"WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC","status":"RECRUITING","sponsor":"AGO Research GmbH","startDate":"2022-05-05","conditions":"Epithelial Ovarian Cancer","enrollment":60},{"nctId":"NCT04245514","phase":"PHASE2","title":"Multimodality Treatment in Stage III Non-small Cell Lung Cancer (NSCLC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Swiss Cancer Institute","startDate":"2020-07-15","conditions":"Non-small Cell Lung Cancer, NSCLC","enrollment":90},{"nctId":"NCT05712356","phase":"PHASE2","title":"A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Lisata Therapeutics, Inc.","startDate":"2023-08-24","conditions":"Cholangiocarcinoma, Gallbladder Cancer, Gallbladder Carcinoma","enrollment":67},{"nctId":"NCT02087423","phase":"PHASE2","title":"A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-02-25","conditions":"Non-Small Cell Lung Cancer","enrollment":446},{"nctId":"NCT03601455","phase":"PHASE2","title":"Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2018-10-26","conditions":"Bladder Urothelial Carcinoma, Stage IV Bladder Cancer AJCC v8, Stage IVA Bladder Cancer AJCC v8","enrollment":13},{"nctId":"NCT04786093","phase":"PHASE2","title":"Durvalumab and Stereotactic Radiotherapy for Advanced NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2021-07-27","conditions":"Non Small Cell Lung Cancer","enrollment":52},{"nctId":"NCT03317158","phase":"PHASE1, PHASE2","title":"Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder","status":"RECRUITING","sponsor":"Noah Hahn, M.D.","startDate":"2017-11-21","conditions":"Urothelial Carcinoma, Bladder Cancer","enrollment":55},{"nctId":"NCT03509012","phase":"PHASE1","title":"Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2018-05-02","conditions":"Carcinoma, Squamous Cell of Head and Neck, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma","enrollment":105},{"nctId":"NCT04364048","phase":"PHASE2","title":"Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer","status":"TERMINATED","sponsor":"Rachel Sanborn","startDate":"2020-06-18","conditions":"Lung Cancer, Non-small Cell Carcinoma","enrollment":10},{"nctId":"NCT04989218","phase":"PHASE1, PHASE2","title":"Durvalumab and Tremelimumab With Platinum-based Chemotherapy in Intrahepatic Cholangiocarcinoma (ICC)","status":"TERMINATED","sponsor":"University of Alabama at Birmingham","startDate":"2023-01-30","conditions":"Cholangiocarcinoma","enrollment":1},{"nctId":"NCT04866017","phase":"PHASE3","title":"A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Participants With Stage III Unresectable Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"BeiGene","startDate":"2021-06-17","conditions":"Non Small Cell Lung Cancer","enrollment":63},{"nctId":"NCT03421353","phase":"PHASE1","title":"AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2018-02-07","conditions":"Advanced Solid Tumours","enrollment":76},{"nctId":"NCT04116047","phase":"PHASE3","title":"CompARE: Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer (OPC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Birmingham","startDate":"2015-07","conditions":"Oropharyngeal Cancer","enrollment":785},{"nctId":"NCT02352948","phase":"PHASE3","title":"A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-01-13","conditions":"Non - Small Cell Lung Cancer NSCLC","enrollment":597},{"nctId":"NCT05935579","phase":"PHASE2","title":"Durvalumab and Lenvatinib With or Without Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2022-12-14","conditions":"Biliary Tract Neoplasms, Immunotherapy","enrollment":40},{"nctId":"NCT02685826","phase":"PHASE1, PHASE2","title":"A Study of Durvalumab in Combination With Lenalidomide With and Without Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma","status":"COMPLETED","sponsor":"Celgene","startDate":"2016-04-25","conditions":"Multiple Myeloma","enrollment":56},{"nctId":"NCT06031597","phase":"PHASE3","title":"Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2023-09-15","conditions":"Non-small Cell Lung Cancer Stage III","enrollment":105},{"nctId":"NCT03473574","phase":"PHASE2","title":"Durvalumab and Tremelimumab With Gemcitabine or Gemcitabine/Cisplatin Compared to Gemcitabine/Cisplatin in CCA Patients","status":"COMPLETED","sponsor":"AIO-Studien-gGmbH","startDate":"2018-05-02","conditions":"Cholangiocarcinoma, Gall Bladder Carcinoma, Cholangiocarcinoma Non-resectable","enrollment":128},{"nctId":"NCT03472274","phase":"PHASE2","title":"Durvalumab (MEDI4736) and TREmelimumab in NEOadjuvant Bladder Cancer Patients (DUTRENEO)","status":"COMPLETED","sponsor":"Fundacion CRIS de Investigación para Vencer el Cáncer","startDate":"2018-10-25","conditions":"Bladder Cancer","enrollment":101},{"nctId":"NCT03975114","phase":"PHASE2","title":"A Study Comparing Immunotherapy With Chemotherapy in the Treatment of Elderly Patients With Advanced NSCLC (MILES-5)","status":"UNKNOWN","sponsor":"National Cancer Institute, Naples","startDate":"2018-12-20","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":460},{"nctId":"NCT05641870","phase":"","title":"Molecular Profiling and Dynamic Changes of ctDNA in Unresectable Locally Advanced NSCLC","status":"UNKNOWN","sponsor":"Parc de Salut Mar","startDate":"2021-02-01","conditions":"Lung Cancer, Stage III Lung Cancer, Unresectable Lung Carcinoma","enrollment":80},{"nctId":"NCT05383001","phase":"PHASE2","title":"Randomized Phase II, Open-label Efficacy and Safety Study of Second-line Durvalumab Plus Tremelimumab Versus Platinum-based Chemotherapy Alone in Patients With NSCLC and First-line Checkpoint-inhibitor Therapy (Re-Check)","status":"WITHDRAWN","sponsor":"AIO-Studien-gGmbH","startDate":"2022-05-20","conditions":"NSCLC Stage IV","enrollment":""},{"nctId":"NCT02777710","phase":"PHASE1","title":"Evaluation of Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With CSF-1R TKI (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal Cancers","status":"COMPLETED","sponsor":"Centre Leon Berard","startDate":"2016-06","conditions":"Colorectal Cancer, Pancreatic Cancer, Metastatic Cancer","enrollment":48},{"nctId":"NCT02805660","phase":"PHASE1, PHASE2","title":"Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLC","status":"TERMINATED","sponsor":"Mirati Therapeutics Inc.","startDate":"2016-06-01","conditions":"Advanced Cancer","enrollment":83},{"nctId":"NCT03721679","phase":"PHASE1, PHASE2","title":"Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1","status":"TERMINATED","sponsor":"Oncovir, Inc.","startDate":"2018-09-25","conditions":"Solid Cancer","enrollment":7},{"nctId":"NCT02423863","phase":"PHASE2","title":"In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol®","status":"COMPLETED","sponsor":"Oncovir, Inc.","startDate":"2015-03","conditions":"Melanoma, Head and Neck Cancer, Sarcoma","enrollment":26},{"nctId":"NCT04621370","phase":"PHASE2","title":"A Trial of Durvalumab (MEDI 4736) in Combination With Extended Neoadjuvant Regimens in Rectal Cancer","status":"UNKNOWN","sponsor":"Liz-Anne Lewsley","startDate":"2020-12-07","conditions":"Rectal Cancer, Rectal Adenocarcinoma, Rectal Neoplasms","enrollment":48},{"nctId":"NCT02658214","phase":"PHASE1","title":"Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-04-28","conditions":"Small Cell Lung Carcinoma, Carcinoma, Squamous Cell of Head and Neck, Stomach Neoplasms","enrollment":32},{"nctId":"NCT03000452","phase":"PHASE2","title":"A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)","status":"COMPLETED","sponsor":"Celgene","startDate":"2017-03-14","conditions":"Multiple Myeloma","enrollment":18},{"nctId":"NCT03150836","phase":"PHASE2","title":"Radiation Therapy and Durvalumab, With or Without Tremelimumab, in Patients With Bladder Cancer","status":"WITHDRAWN","sponsor":"Terence Friedlander, MD","startDate":"2017-10-01","conditions":"Bladder Cancer","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Durvalumab (Regimen 2)","genericName":"Durvalumab (Regimen 2)","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Durvalumab is a PD-L1 inhibitor that blocks the interaction between PD-L1 on tumor cells and PD-1/PD-L2 on immune cells, thereby restoring anti-tumor immune responses. Used for Unresectable stage III non-small cell lung cancer (NSCLC) after concurrent chemoradiotherapy, Metastatic or unresectable locally advanced urothelial carcinoma, Biliary tract cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}